Operating EBITDA grew by 82.7 % to Rs. 14.4 crore, EBITDA margin at 23.9%, and Profit After Tax (PAT) grew by 47.1% to Rs. 7.8 crore
The initiative launched in 2019 has touched over 10,000 lives with 500+ screening camps and aims to double its reach in the next 2 years
Theramex were searching for a platform to digitise the manual processes across their R&D landscape
During the quarter, foreign exchange fluctuations had an impact of Rs. 4.56 crore Q3 FY23 Profit After Tax after considering exchange rate fluctuations stood at Rs. 8.2 crore
DETAF would be a welcome new addition in the management of HIV infections and will be available for supplies to low- and middle-income countries
CHMP recommendation is based on Phase III data, which demonstrated that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel significantly reduced the risk of death by 32.5%
Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY
It is administered as a single infusion 30 minutes prior to the start of each chemotherapy cycle that helps prevent, both, acute and delayed phases of CINV
The company is adding new capabilities of Combi-line for Microsphere, additional Bag line and lyos for the Penem block in Pashamylaram facility in Hyderabad and will be earmarking capital for further building on its Biosimilar CDMO facility
OrbiMed's exercise of warrant conversion will further strengthen the company's net cash position to over Rs.650 crores.
Subscribe To Our Newsletter & Stay Updated
